JNJ

233.45

+2.12%↑

ISRG

491.45

-1.68%↓

ABT

108.22

-2.08%↓

RDY

13.8

+4.94%↑

NEOG

10.82

+4.84%↑

JNJ

233.45

+2.12%↑

ISRG

491.45

-1.68%↓

ABT

108.22

-2.08%↓

RDY

13.8

+4.94%↑

NEOG

10.82

+4.84%↑

JNJ

233.45

+2.12%↑

ISRG

491.45

-1.68%↓

ABT

108.22

-2.08%↓

RDY

13.8

+4.94%↑

NEOG

10.82

+4.84%↑

JNJ

233.45

+2.12%↑

ISRG

491.45

-1.68%↓

ABT

108.22

-2.08%↓

RDY

13.8

+4.94%↑

NEOG

10.82

+4.84%↑

JNJ

233.45

+2.12%↑

ISRG

491.45

-1.68%↓

ABT

108.22

-2.08%↓

RDY

13.8

+4.94%↑

NEOG

10.82

+4.84%↑

Начало・Списък с акции・Anavex Life Sciences Corp

Anavex Life Sciences Corp

Отворен

СекторЗдравеопазване

4.53 -0.88

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

4.49

Максимум

4.6899999999999995

Ключови измерители
By Trading Economics
Приходи	3.4M -9.8M
Служители	34
EBITDA	-2.1M -13M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+325.53% upside

Дивиденти
By Dow Jones
Следващи печалби	11.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	184M 449M
Предишно отваряне	5.41
Предишно затваряне	4.53

Настроения в новините

By Acuity

50%

147 / 352 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

8.275 / 9.312 Подкрепа & съпротива

Anavex Life Sciences Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

2.02.2026 г., 23:52 ч. UTC

Придобивния, сливания и поглъщания

Elliott Management Doesn't Plan to Tender Its Shares at the Current Terms

2.02.2026 г., 23:52 ч. UTC

Придобивния, сливания и поглъщания

Elliott Management: Toyota Fudosan Revised Tender Offer for Toyota Industries 'Very Significantly Undervalues' Company

2.02.2026 г., 23:48 ч. UTC

Пазарно говорене

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

2.02.2026 г., 23:38 ч. UTC

Пазарно говорене

Gold Rises on Likely Technical Recovery, Dip-Buying Interest -- Market Talk

2.02.2026 г., 23:28 ч. UTC

Пазарно говорене

SpaceX, xAI Deal Further Consolidates Musk's Businesses -- Market Talk

2.02.2026 г., 23:23 ч. UTC

Печалби

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- 2nd Update

2.02.2026 г., 22:57 ч. UTC

Печалби

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2.02.2026 г., 22:22 ч. UTC

Придобивния, сливания и поглъщания

What the Blockbuster SpaceX--xAI Merger Can Mean for Tesla Stock -- Barrons.com

2.02.2026 г., 22:08 ч. UTC

Пазарно говорене

Australian Inflation Woes Rooted In Excess Govt Spending -- Market Talk

2.02.2026 г., 21:51 ч. UTC

Печалби

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

2.02.2026 г., 21:49 ч. UTC

Печалби

Disney's Streaming Profit Surges as CEO Decision Approaches -- 5th Update

2.02.2026 г., 21:39 ч. UTC

Печалби

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2.02.2026 г., 21:36 ч. UTC

Печалби

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- Update

2.02.2026 г., 21:34 ч. UTC

Печалби

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2.02.2026 г., 21:28 ч. UTC

Придобивния, сливания и поглъщания

What a SpaceX--xAI Merger Could Mean for Tesla Stock -- Barrons.com

2.02.2026 г., 21:23 ч. UTC

Печалби

BYD, Chinese EV Stock Plunge On Weak Data. What That Means for Tesla Stock. -- Barrons.com

2.02.2026 г., 21:19 ч. UTC

Печалби

Palantir Technologies: U.S. Commercial Business Growing at 'Astonishing' Rate, Generating $507 Million Last Quarter, 137% Increase Over the Same Period the Year Before >PLTR

2.02.2026 г., 21:17 ч. UTC

Печалби

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- WSJ

2.02.2026 г., 21:17 ч. UTC

Печалби

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2.02.2026 г., 21:10 ч. UTC

Печалби

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2.02.2026 г., 21:08 ч. UTC

Печалби

Palantir Technologies: Rule of 40 Score Is Now 127% >PLTR

2.02.2026 г., 21:07 ч. UTC

Печалби

Palantir Technologies: Sees 2026 U.S. Comml Rev in Excess of $3.144B, Representing Growth Rate of at Least 115% >PLTR

2.02.2026 г., 21:05 ч. UTC

Печалби

Palantir Technologies 4Q Net $608.7M >PLTR

2.02.2026 г., 21:05 ч. UTC

Печалби

Palantir Technologies 4Q Rev $1.41B >PLTR

2.02.2026 г., 21:05 ч. UTC

Печалби

Palantir Technologies Sees 1Q Rev $1.53B-$1.54B >PLTR

2.02.2026 г., 21:05 ч. UTC

Печалби

Palantir Technologies Sees FY Rev $7.18B-$7.2B >PLTR

2.02.2026 г., 21:05 ч. UTC

Печалби

Palantir Technologies 4Q Adj EPS 25c >PLTR

2.02.2026 г., 21:05 ч. UTC

Печалби

Palantir Technologies 4Q EPS 24c >PLTR

2.02.2026 г., 20:40 ч. UTC

Пазарно говорене

Treasury Yields, Dollar Rise Amid Signs of Resilient U.S. Economy -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Anavex Life Sciences Corp Прогноза

Ценова цел

By TipRanks

325.53% нагоре

12-месечна прогноза

Среден 20 USD 325.53%

Висок 20 USD

Нисък 20 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Anavex Life Sciences Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

2 ratings

Купи

Задържане

Продай

Според 2 анализатори, дали борсови рейтинги на Anavex Life Sciences Corp през последните 3 месеца.

Техническа оценка

By Trading Central

8.275 / 9.312Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Настроение

By Acuity

147 / 352 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.